Advanced urothelial cancer: a radiology update

被引：4
作者：
Alessandrino, Francesco [1 ,2 ]
Ghaith, Ola [1 ,2 ]
Williams, Kristin [1 ,2 ]
Sonpavde, Guru P. [3 ]
Silverman, Stuart G. [2 ]
Shinagare, Atul B. [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
来源：
ABDOMINAL RADIOLOGY | 2019年 / 44卷 / 12期
关键词：
Urothelial carcinoma; Transitional cell; Urinary bladder neoplasms; Computed tomography; X-ray; Programmed cell death-1 receptor; Neoplasm; Metastasis; INVASIVE BLADDER-CANCER; CISPLATIN-INELIGIBLE PATIENTS; SOLID TUMORS; METASTATIC PATTERN; RESPONSE CRITERIA; ADVERSE EVENTS; SINGLE-ARM; OPEN-LABEL; CARCINOMA; CT;
D O I：
10.1007/s00261-019-02148-3
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The recent genomic characterization of urothelial carcinoma by the Cancer Genome Atlas Project, made possible by the introduction of high throughput, reduced cost, and sequence analysis, has shed new insights on the biology of advanced disease. In addition, studies on imaging of advanced urothelial carcinoma have widened the knowledge on disease presentation and on pattern of metastatic spread and their correlation with the underlying biology of urothelial carcinoma. The wide range of treatments for advanced urothelial cancer, including combined chemotherapy regimens and immune checkpoint inhibitors, each result in treatment class-specific patterns of response and adverse events. Results of studies point to the need for a reliable biomarker, perhaps with imaging, that predicts prognosis and treatment response to systemic treatment, and can be used to select the most effective treatment while minimizing toxicity. This review of advanced urothelial cancer introduces the latest advances in genetic profiling, the current role of imaging, the radiographic appearance of treatment response and their toxicities, and details potential future areas of imaging research.
引用
收藏
页码：3858 / 3873
页数：16
相关论文
共 100 条
[21]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[22]   HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts [J].
Eriksson, Pontus ;
Sjodahl, Gottfrid ;
Chebil, Gunilla ;
Liedberg, Fredrik ;
Hoglund, Mattias .
ONCOTARGET, 2017, 8 (30) :48905-48914
[23]   Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal [J].
Fife, Brian T. ;
Pauken, Kristen E. ;
Eagar, Todd N. ;
Obu, Takashi ;
Wu, Jenny ;
Tang, Qizhi ;
Azuma, Miyuki ;
Krummel, Matthew F. ;
Bluestone, Jeffrey A. .
NATURE IMMUNOLOGY, 2009, 10 (11) :1185-U70
[24]   A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy [J].
Galsky, Matthew D. ;
Hahn, Noah M. ;
Rosenberg, Jonathan ;
Sonpavde, Guru ;
Hutson, Thomas ;
Oh, William K. ;
Dreicer, Robert ;
Vogelzang, Nicholas ;
Sternberg, Cora ;
Bajorin, Dean F. ;
Bellmunt, Joaquim .
LANCET ONCOLOGY, 2011, 12 (03) :211-214
[25]   Quantifying tumour heterogeneity with CT [J].
Ganeshan, Balaji ;
Miles, Kenneth A. .
CANCER IMAGING, 2013, 13 (01) :140-149
[26]  
Ghafoori M, 2013, UROL J, V10, P866
[27]   ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy [J].
Groenendijk, Floris H. ;
de Jong, Jeroen ;
van de Putte, Elisabeth E. Fransen ;
Michaut, Magali ;
Schlicker, Andreas ;
Peters, Dennis ;
Velds, Arno ;
Nieuwland, Marja ;
van den Heuvel, Michel M. ;
Kerkhoven, Ron M. ;
Wessels, Lodewijk F. ;
Broeks, Annegien ;
van Rhijn, Bas W. G. ;
Bernards, Rene ;
van der Heijden, Michiel S. .
EUROPEAN UROLOGY, 2016, 69 (03) :384-388
[28]  
Hagner Nicole, 2010, Cancer Manag Res, V2, P293, DOI 10.2147/CMR.S10043
[29]   ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging - A report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology [J].
Hendel, Robert C. ;
Patel, Manesh R. ;
Kramer, Christopher M. ;
Poon, Michael ;
Hendel, Robert C. ;
Brindis, Ralph G. ;
Hendel, Robert C. ;
Douglas, Pamela S. ;
Peterson, Eric D. ;
Wolk, Michael J. ;
Allen, Joseph M. ;
Patel, Manesh R. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (07) :1475-1497
[30]   The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours [J].
Humphrey, Peter A. ;
Moch, Holger ;
Cubilla, Antonio L. ;
Ulbright, Thomas M. ;
Reuter, Victor E. .
EUROPEAN UROLOGY, 2016, 70 (01) :106-119
12345678910